Evidence map›Paper›PMID 26154421›Full record

ArticlePLoS neglected tropical diseases2015

A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.

Md Abu Sayeed, Meagan Kelly Bufano, Peng Xu, Grace Eckhoff, Richelle C Charles, Mohammad Murshid Alam, Tania Sultana, Md Rasheduzzaman Rashu, Amanda Berger, Geoffrey Gonzalez-Escobedo and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in medicine · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Virus-like Particle Display ofACS infectious diseases · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Md Abu SayeedDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Center for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
Meagan Kelly BufanoDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Peng XuNational Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), Laboratory of Bioorganic Chemistry (LBC), National Institutes of Health, Bethesda, Maryland, United States of America.
Grace EckhoffHarvard Medical School, Boston, Massachusetts, United States of America.
Richelle C CharlesDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America.
Mohammad Murshid AlamDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Center for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
Tania SultanaDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Center for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
Md Rasheduzzaman RashuDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Center for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
Amanda BergerDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Geoffrey Gonzalez-EscobedoDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Anjali MandlikDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Taufiqur Rahman BhuiyanDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Center for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
Daniel T LeungDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Division of Infectious Disease, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Regina C LaRocqueDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Jason B HarrisDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America.
Stephen B CalderwoodDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Firdausi QadriCenter for Vaccine Sciences, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh.
W F VannCenter for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Laboratory of Bacterial Toxins, Bethesda, Maryland, United States of America.
Pavol KováčHarvard Medical School, Boston, Massachusetts, United States of America.
Edward T RyanDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America; Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Massachusetts General Hospital · USHarvard University · USInternational Centre for Diarrhoeal Disease Research · BDCenter for Biologics Evaluation and Research · USNational Institutes of Health · US

Funding

Protecutive immunity to human cholera in BangladeshU01AI058935 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CALDERWOOD, STEPHEN B., RYAN, EDWARD T. · 2003 to 2014
$7.8M
Training program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4M
O-Specific Polysaccharide Responses and CholeraR37AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Edward T. Ryan · 2020 to 2026
$5.1M
O-Specific Polysaccharide Responses and CholeraR01AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2014 to 2018
$3.7M
O-Specific Polysaccharide Responses and CholeraR56AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2013 to 2020
$843k
High-throughput proteomic study of protective immunity in human cholera infectionK08AI089721 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHARLES, RICHELLE C · 2010 to 2014
$684k
FIC NIH HHS D43 TW005572FIC NIH HHS TW005572Intramural NIH HHSNIAID NIH HHS K08 AI089721NIAID NIH HHS R01 AI106878NIAID NIH HHS R37 AI106878NIAID NIH HHS U01 AI058935NIAID NIH HHS U01 AI106878
6 · The paper itself

Abstract

backgroundVibrio cholerae is the cause of cholera, a severe watery diarrhea. Protection against cholera is serogroup specific. Serogroup specificity is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS). METHODOLOGY: Here we describe a conjugate vaccine for cholera prepared via squaric acid chemistry from the OSP of V. cholerae O1 Inaba strain PIC018 and a recombinant heavy chain fragment of tetanus toxin (OSP:rTTHc). We assessed a range of vaccine doses based on the OSP content of the vaccine (10-50 μg), vaccine compositions varying by molar loading ratio of OSP to rTTHc (3:1, 5:1, 10:1), effect of an adjuvant, and route of immunization. PRINCIPLE

findingsImmunized mice developed prominent anti-OSP and anti-TT serum IgG responses, as well as vibriocidal antibody and memory B cell responses following intramuscular or intradermal vaccination. Mice did not develop anti-squarate responses. Intestinal lamina proprial IgA responses targeting OSP occurred following intradermal vaccination. In general, we found comparable immune responses in mice immunized with these variations, although memory B cell and vibriocidal responses were blunted in mice receiving the highest dose of vaccine (50 μg). We found no appreciable change in immune responses when the conjugate vaccine was administered in the presence or absence of immunoadjuvant alum. Administration of OSP:rTTHc resulted in 55% protective efficacy in a mouse survival cholera challenge model.

conclusionWe report development of an Inaba OSP:rTTHc conjugate vaccine that induces memory responses and protection against cholera in mice. Development of an effective cholera conjugate vaccine that induces high level and long-term immune responses against OSP would be beneficial, especially in young children who respond poorly to polysaccharide antigens.

Indexed as

AdolescentAdultAnimalsAntibodies, BacterialChildChild, PreschoolCholeraCholera VaccinesDisease Models, AnimalFemaleHumansImmunizationImmunologic MemoryMaleMiceMiddle AgedAntibodies, BacterialCholera VaccinesO AntigensTetanus ToxinVaccines, Conjugate

Identifiers

PMID26154421
PMCPMC4495926
OpenAlexW818949034

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.